{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:20:35Z","timestamp":1790511635885,"version":"4.1.0"},"reference-count":44,"publisher":"European Respiratory Society (ERS)","issue":"127","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2012,12,17]]},"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:p>The mainstay in smoking cessation is counselling in combination with varenicline, nicotine replacement therapy (NRT) or bupropion SR. Varenicline and combination of two NRTs is equally effective, while varenicline alone is more effective than either NRT or bupropion SR. NRT is extremely safe but cardiovascular and psychiatric adverse events with varenicline have been reported. These treatments have also been shown to be effective in patients with chronic obstructive pulmonary disease (COPD).<\/jats:p><jats:p>A model study is the Lung Health Study from the USA. Findings from this study of 5,587 patients with mild COPD showed that repeated smoking cessation for a period of 5 yrs resulted in a quit rate of 37%. After 14.5 yrs the quitters had a higher lung function and a higher survival rate. A study with a new nicotine formulation, a mouth spray, showed high relative efficacy. As 5\u201310% of quitters use long-term NRT, we report the results of a study where varenicline compared with placebo increased the quit rate in long-term users of NRT.<\/jats:p><jats:p>Smoking cessation is the most effective intervention in stopping the progression of COPD, as well as increasing survival and reducing morbidity. This is why smoking cessation should be the top priority in the treatment of COPD.<\/jats:p>","DOI":"10.1183\/09059180.00007212","type":"journal-article","created":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T20:45:33Z","timestamp":1362170733000},"page":"37-43","source":"Crossref","is-referenced-by-count":146,"title":["Smoking cessation and COPD"],"prefix":"10.1183","volume":"22","author":[{"given":"Philip","family":"T\u00f8nnesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2013,2,28]]},"reference":[{"key":"2025042405151148000_22.127.37.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)10019-3"},{"key":"2025042405151148000_22.127.37.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2005.08.004"},{"key":"2025042405151148000_22.127.37.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2004.03.017"},{"key":"2025042405151148000_22.127.37.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063070"},{"key":"2025042405151148000_22.127.37.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7245.1297"},{"key":"2025042405151148000_22.127.37.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200707-973OC"},{"key":"2025042405151148000_22.127.37.7","doi-asserted-by":"crossref","unstructured":"Huang Y Britton J Hubbard R . Who receives prescriptions for smoking cessation medications? An association rule mining analysis using a large primary care database. Tob Control 2012 [Epub ahead of print DOI: 10.1136\/tobaccocontrol-2011-050124].","DOI":"10.1136\/tobaccocontrol-2011-050124"},{"key":"2025042405151148000_22.127.37.8","unstructured":"Fiore MC Bailey WC Cohen SJ . Treating tobacco use and dependence. Clinical Practice Guideline. Rockville, U.S. Department of Health and Human Services, 2008."},{"key":"2025042405151148000_22.127.37.9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000146.pub4"},{"key":"2025042405151148000_22.127.37.10","first-page":"CD006103","article-title":"Nicotine receptor partial agonists for smoking cessation","volume":"4","author":"Cahill","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042405151148000_22.127.37.11","first-page":"CD000031","article-title":"Antidepressants for smoking cessation","volume":"1","author":"Hughes","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042405151148000_22.127.37.12","unstructured":"National Institute for Clinical Excellence. Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. National Institute for Clinical Excellence Technology Appraisal Guidance No. 39. 2002. http:\/\/www.nice.org.uk\/TA039 Date last updated: December 20, 2011. Date last accessed: January 2, 2013."},{"key":"2025042405151148000_22.127.37.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03770.x"},{"key":"2025042405151148000_22.127.37.14","first-page":"CD002850","article-title":"Telephone counselling for smoking cessation","volume":"1","author":"Stead","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042405151148000_22.127.37.15","first-page":"CD001007","article-title":"Group behaviour therapy programmes for smoking cessation","volume":"2","author":"Stead","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042405151148000_22.127.37.16","doi-asserted-by":"publisher","DOI":"10.1080\/14622200802023890"},{"key":"2025042405151148000_22.127.37.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4603(97)00073-7"},{"key":"2025042405151148000_22.127.37.18","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1998.tb05787.x"},{"key":"2025042405151148000_22.127.37.19","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00155811"},{"key":"2025042405151148000_22.127.37.20","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.2.334"},{"key":"2025042405151148000_22.127.37.21","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0865"},{"key":"2025042405151148000_22.127.37.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04724-3"},{"key":"2025042405151148000_22.127.37.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1988.03410110101035"},{"key":"2025042405151148000_22.127.37.24","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400100073012"},{"key":"2025042405151148000_22.127.37.25","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/nts146"},{"key":"2025042405151148000_22.127.37.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2006.00955.x"},{"key":"2025042405151148000_22.127.37.27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.1.47"},{"key":"2025042405151148000_22.127.37.28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.1.56"},{"key":"2025042405151148000_22.127.37.29","doi-asserted-by":"crossref","first-page":"JC4","DOI":"10.7326\/0003-4819-155-8-201110180-02005","article-title":"ACP Journal Club. Review: varenicline increases risk for serious adverse cardiovascular events in tobacco users","volume":"155","author":"Brophy","year":"2011","journal-title":"Ann Intern Med"},{"key":"2025042405151148000_22.127.37.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e2856"},{"key":"2025042405151148000_22.127.37.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b3805"},{"key":"2025042405151148000_22.127.37.32","unstructured":"Food US , Drug Administration. FDA Drug Safety Communication: safety review update of Chantix (varenicline) and risk of cardiovascular adverse events. www.fda.gov\/Drugs\/DrugSafety\/ucm330367.htm Date last updated: December 13, 2012. Date last accessed: January 2, 2013."},{"key":"2025042405151148000_22.127.37.33","doi-asserted-by":"publisher","DOI":"10.1080\/14622200701705027"},{"key":"2025042405151148000_22.127.37.34","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831110-00006"},{"key":"2025042405151148000_22.127.37.35","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00167708"},{"key":"2025042405151148000_22.127.37.36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03520190043033"},{"key":"2025042405151148000_22.127.37.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2005.08.003"},{"key":"2025042405151148000_22.127.37.38","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.19.2286"},{"key":"2025042405151148000_22.127.37.39","doi-asserted-by":"publisher","DOI":"10.3109\/10826089109056242"},{"key":"2025042405151148000_22.127.37.40","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246161"},{"key":"2025042405151148000_22.127.37.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)64863-5"},{"key":"2025042405151148000_22.127.37.42","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2112096"},{"key":"2025042405151148000_22.127.37.43","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-4-200502150-00005"},{"key":"2025042405151148000_22.127.37.44","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00060806"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/09059180.00007212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T12:15:24Z","timestamp":1745496924000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/09059180.00007212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,28]]},"references-count":44,"journal-issue":{"issue":"127","published-online":{"date-parts":[[2013,2,28]]},"published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1183\/09059180.00007212"],"URL":"https:\/\/doi.org\/10.1183\/09059180.00007212","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,28]]}}}